Premium
High stromal transforming growth factor β–induced expression is a novel marker of progression and poor prognosis in gastric cancer
Author(s) -
Suzuki Masaki,
Yokobori Takehiko,
Gombodorj Navchaa,
Yashiro Masakazu,
Turtoi Andrei,
Handa Tadashi,
Ogata Kyoichi,
Oyama Tetsunari,
Shirabe Ken,
Kuwano Hiroyuki
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25217
Subject(s) - tgfbi , stromal cell , cancer , cancer research , downregulation and upregulation , transforming growth factor , medicine , immunohistochemistry , cancer cell , extracellular matrix , pathology , biology , microbiology and biotechnology , gene , biochemistry
Background and Objectives Transforming growth factor β‐induced (TGFBI) protein is a secreted extracellular matrix protein with conflicting roles in cancer, acting as a tumour suppressor and a promoter, which appears to be tissue specific. The role of TGFBI in gastric cancer (GC) remains unclear, which we aimed to investigate using the clinical samples as well as an in vitro coculture model of GC. Methods The clinical significance of TGFBI was assessed in 208 GC samples using immunohistochemistry. Molecular function of TGFBI in the GC cells was examined by small interfering RNA‐mediated TGFBI downregulation in the gastric fibroblasts cocultured with the GC cells. Results TGFBI expression was localised mainly in the cancer stroma and not in the noncancerous gastric tissue or the GC cells. High TGFBI expression was significantly associated with poor prognosis and cancer progression. Downregulation of TGFBI in the cocultured gastric fibroblasts inhibited the invasion and migration abilities of the GC cells. Conclusions High stromal TGFBI expression might be a useful predictive marker for poor prognosis in GC patients. Furthermore, TGFBI in the cancer stromal cells is a promising target for GC treatment.